Human Molecular Genetics, 2013, Vol. 22, No. 1
doi:10.1093/hmg/dds399
Advance Access published on October 1, 2012
51–60
Expression of wild-type human superoxide
dismutase-1 in mice causes amyotrophic lateral
sclerosis
Karin S. Graffmo1,{, Karin Forsberg1,{, Johan Bergh1, Anna Birve2, Per Zetterström1,
Peter M. Andersen2, Stefan L. Marklund1,∗ and Thomas Brännström1
1
Department of Medical Biosciences and 2Department of Pharmacology and Clinical Neuroscience,
Umeå University, SE-901 85 Umeå, Sweden
Received June 19, 2012; Revised August 21, 2012; Accepted September 18, 2012
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is characterized by progressive loss of upper and lower motor neurons, which
results in paralysis and finally death from respiratory failure.
While most of the cases appear to be sporadic, at least 10%
of the patients show a familial predisposition. More than 10
ALS-associated genes have been identified in families so far;
the most common being C9ORF72, superoxide dismuatase-1
(SOD1), TAR-DNA binding protein-43 (TDP43) and fused
in sarcoma (FUS). Mutations in these are also occasionally
found in apparently sporadic patients (1). The underlying
causes of the remaining ALS cases are unknown. In several
other neurodegenerative conditions such as Alzheimer’s,
Parkinson’s and Creutzfeldt-Jacob’s diseases, some of the proteins found mutated in families are also thought to be involved
in the pathogenesis in patients lacking such mutations (2).
Could the same situation pertain to ALS? Neuronal cytosolic
inclusions containing TDP43 are found in cases carrying
mutations in the gene, but usually also in apparently sporadic
ALS patients and patients carrying some other ALS-linked
mutations (3). Based on such findings, it has been suggested
that TDP43 might more generally be involved in ALS pathogenesis. The disease caused by mutations in SOD1 has been
regarded as an entity separate from ALS in general, since
TDP43 inclusions are not found in the motor neurons (3).
There is, however, circumstantial evidence suggesting that
the wild-type (wt) human SOD1 (wt-hSOD1) might commonly be involved in ALS. Inclusions containing aggregated
SOD1 are considered hallmarks of ALS caused by mutant
SOD1s (4 – 6), but can with a set of antibodies specific for misfolded hSOD1 species also regularly be demonstrated in motor
neuron somas (7) and glial cell nuclei (8) of ALS patients
lacking SOD1 mutations. Other antibodies reactive with an
epitope in mutant SOD1 or in misfolded SOD1 have been
found to stain motor neuron somas (9) and axons (10) in
some patients with sporadic ALS. Astrocytes generated from
sporadic ALS patients are toxic to cocultured motor neurons,
an effect that is attenuated by SOD1 knockdown (11). In old
mice expressing wt-hSOD1 (12), a loss of motor neurons
∗
To whom correspondence should be addressed at: Department of Medical Biosciences, Umeå University, SE 90185 Umeå, Sweden.
Tel: +46 907851239; Fax: +46 907854484; Email: stefan.marklund@medbio.umu.se
†
The authors wish it to be known that these should be regarded as joint First Authors.
# The Author 2012. Published by Oxford University Press. All rights reserved.
For Permissions, please email: journals.permissions@oup.com
Downloaded from http://hmg.oxfordjournals.org/ by guest on April 30, 2016
A common cause of amyotrophic lateral sclerosis (ALS) is mutations in the gene encoding superoxide dismutase-1. There is evolving circumstantial evidence that the wild-type protein can also be neurotoxic and
that it may more generally be involved in the pathogenesis of ALS. To test this proposition more directly,
we generated mice that express wild-type human superoxide dismutase-1 at a rate close to that of mutant
superoxide dismutase-1 in the commonly studied G93A transgenic model. These mice developed an ALSlike syndrome and became terminally ill after around 370 days. The loss of spinal ventral neurons was similar
to that in the G93A and other mutant superoxide dismutase-1 models, and large amounts of aggregated
superoxide dismutase-1 were found in spinal cords, but also in the brain. The findings show that wild-type
human superoxide dismutase-1 has the ability to cause ALS in mice, and they support the hypothesis of a
more general involvement of the protein in the disease in humans.
52
Human Molecular Genetics, 2013, Vol. 22, No. 1
Table 1. Expression of hSOD1 mRNA in the brain of transgenic strains
Strain
Background
Percent of level in G93A mice
G93A hemizygous
Wt-hSOD1 hemizygous
Wt-hSOD1 hemizygous
Wt-hSOD1 homozygous
C57Bl/6
C57Bl/6
CBA
CBA
100
54.4 + 10.1
45.0 + 9.1
76.3 + 12.0
Messenger RNA was analyzed by northern blot. The results were normalized
against b-actin. The values are means + SD of results for three 100-day-old
mice of each strain which were analyzed twice. They are expressed as
percentages of values for three G93A mice which were analyzed in parallel.
Figure 1. Weight development of the mice. (A) Female mice: CBA control
(filled squares, n ¼ 14), wt-hSOD1 hemizygous (open circles, n ¼ 11) and
wt-hSOD1 homozygous mice (filled triangles, n ¼ 11). (B) Male mice: CBA
control (filled squares, n ¼ 19), wt-hSOD1 hemizygous (open circles, n ¼
20) and wt-hSOD1 homozygous mice (filled triangles, n ¼ 19). The mice
were weighed once a week.
RESULTS
Mice expressing wt-hSOD1 at a high-level develop deadly
motor neuron disease
To increase the expression of wt-hSOD1, we initially crossed
the hemizygous N1029 mice (12) on C57Bl/6 background to
generate homozygotes for the transgene insertion. Only few
homozygous pups were born, however, which is why we
instead tested mice with the CBA genetic background. On
that background homozygous, pups were born at apparently
Mendelian rates: among 79 pups 21.5% were homozygotes,
59.5% hemizygotes and 19.5% non-transgenic. The expression
rate of wt-hSOD1 in the homozygotes was assessed by northern blots and found to be close to that of mutant hSOD1 in
G93A mice (Table 1). The wt-hSOD1 homozygous mice
showed a slower weight development than hemizygous and
non-transgenic CBA mice, but they appeared otherwise
normal as pups and young adults (Fig. 1).
Figure 2. Kaplan– Meyer diagram showing the cumulative survival of homozygous wt-hSOD1 mice. The median survival time was 367 days.
Downloaded from http://hmg.oxfordjournals.org/ by guest on April 30, 2016
can be demonstrated, although the lifespan is not shortened
(13,14). Wt-hSOD1 expression in mice also exacerbates
disease caused by mutant hSOD1s (13,15 – 17). Although
most ALS-linked mutant hSOD1s show low structural stabilities, some are close and even equal to that of wt-hSOD1,
which in turn is much less stable than the murine SOD1
(18– 20). Accordingly, misfolded mutant hSOD1s can in cultured cells induce misfolding of the moderately stable
wt-hSOD1 and the process thereafter seems to propagate independent of the mutant hSOD1s (21).
To examine the ALS-causing ability of wt-hSOD1 more directly, we here studied the effects of overexpressing the protein
in mice. To cause disease within the short lifespan of mice,
mutant hSODs have to be expressed at rates around 25-fold
higher than that of the endogenous murine SOD1 (14). Furthermore, the toxicity in the transgenic ALS models is
highly dependent on the expression rate: for a given mutant,
a doubling broadly halves the lifespan (6,14,19). In the most
commonly studied murine model, G93A mutant hSOD1 is
expressed at a very high rate, around double that seen in
many other current models including mice expressing
wt-hSOD1 (12,14,19). In this study, we aimed at expressing
wt-hSOD1 in mice at a rate close to that seen in the G93A
model. The mice generated developed a fatal ALS-like
disease, mimicking that seen in mice expressing mutant
hSOD1s. The findings lend further support to the idea that
wt-hSOD1 may generally be involved in ALS in humans.
Human Molecular Genetics, 2013, Vol. 22, No. 1
53
At an average of 253 + 46 (SD) days of age, the mice
started showing evidence of hindleg paresis in the form of deficient leg splaying. At a mean age of 367 + 56 (SD; n ¼ 25)
days of age, the mice were deemed terminally ill and were
killed (Fig. 2). For comparison, the G93A mice currently
live 155 + 9 (SD; n ¼ 170) days in our laboratory. The principal symptoms were progressive hindleg paresis similar to
that seen in the G93A and D90A hSOD1 transgenic models
(14,19). The weights did not reach normal values at any age,
and a weight loss was seen during the final 100 days
(Fig. 1). Hemizygous wt-hSOD1 CBA mice had a normal lifespan and no obvious motor neuron phenotype. Their weight
development was similar to that observed in non-transgenic
CBA mice (Fig. 1).
A deviant feature in the homozygous mice is an ataxic staggering gait, which appears at around 200 days. This staggering
is also seen in hemizygous wt-hSOD1 transgenic mice on both
CBA and C57Bl/6 background starting at ≏450 days, but has
not been observed in any of the four mutant hSOD1 transgenic
ALS models [G85R, D90A, G93A, G127instggg (G127X)]
kept in our laboratory.
CNS histopathology
In the spinal cord, diffuse staining of misfolded hSOD1 was
seen in motor neurons already at 100 days of age in
wt-hSOD1 homozygous mice and was aggravated in terminally ill mice. The staining was mostly cytoplasmic, although in
some cases it could also be seen in the nuclei (Fig. 3B and G).
Terminally ill mice showed severe loss of motor neurons and
the remaining cells were pyknotic and showed the disruption
of integrity. In addition, cytoplasmic staining of misfolded
Downloaded from http://hmg.oxfordjournals.org/ by guest on April 30, 2016
Figure 3. Histopathological examinations of the central nervous system (CNS). Staining of misfolded hSOD1, vacuolization and heavy cell loss in CNS of transgenic mice expressing wt-hSOD1. Micrographs show staining of ventral horns, cerebellum and hippocampus/subiculum with the 131–153 anti-hSOD1 peptide
rabbit antibody. The mice were homozygous for wt-hSOD1 and were 100 days old (A– E) or terminally ill (F –J); hemizygous for wt-hSOD1 and 350-day old
(K– O); and non-transgenic littermates 350-day old (P– T). Already at 100 days, heavy staining of misfolded wt-hSOD1 was seen in the motor neurons (A and B)
and Purkinje cells (C and D) of mice homozygous for wt-hSOD1. In the terminal stage, extensive loss of motor neurons along with heavy vacuolization is seen in
the ventral horns (F and G) and loss of Purkinje cells and vacuolization in the cerebellum (H and I). Heavy vacuolization is seen in the hippocampal area (J).
Arrows show the subiculum. Intranuclear staining of misfolded wt-hSOD1 was seen in glial cells (arrowheads in B, G and L). Scale bars represent 50 mm (A, C,
F, H, K, M, P and R) and 20 mm (B, D, E, G, I, J, L, N, O, Q, S and T).
54
Human Molecular Genetics, 2013, Vol. 22, No. 1
Table 2. Numbers of neurons in the thoracic spinal cord ventral horns of transgenic and non-transgenic control mice
Strain
Mean + SD
Homozygous
Wt-hSOD1 tg mice (n ¼ 8)
Hemizygous
Wt-hSOD1 tg mice (n ¼ 5)
Non-transgenic
CBA mice (n ¼ 5)
134 700 + 29 700 (mean age 340 + 50 days)
153 500 + 25 600 (mean age 403 + 7 days)
229 800 + 28 200 (mean age 335 + 14 days)
The homozygous wt-hSOD1 mice were terminally ill, and the hemizygous
mice and CBA controls were examined at matching ages.
Expression of hSOD1 in tissues
The content of wt-hSOD1 was determined in the spinal cord,
brain, liver and muscle at around 100 days and in terminal/
350-day-old mice (Table 3). In the spinal cord and brain
from 100-day-old wt-hSOD1 homozygotes, the levels were
twice as high as in hemizygotes and around 4-fold as high
as in G93A mice (14,19). The wt-hSOD1 accounted for
3– 4% of the soluble protein in the central nervous system
(CNS) tissues (Table 3). If the murine SOD1 in CBA controls
is fully active and has the same specific activity as wt-hSOD1,
the enzymatic activity data suggest that it accounts for 0.06%
of the total soluble tissue protein. The levels of wt-hSOD1
protein in the homozygotes thus appear to be some 50-fold
higher than the level of endogenous murine SOD1. In
100-day-old homozygous mice, the proportion of wt-hSOD1
with a reduced C57-C146 disulfide bond was higher in the
spinal cord than in the brain and cerebellum but became
lower in terminally ill mice (Table 3). As previously observed
in G93A and D90A mice which also express high levels of
hSOD1 (14), most of the protein lacked enzymatic activity.
We calculated that the proportion active SOD1 in the homozygous spinal cord was ≏15%, using the specific activity of
native Cu-charged hSOD1 (18,23). The proportion active
SOD1 was somewhat higher in the brain and cerebellum and
much higher in the liver and muscle. This low enzymatic activity of the hSOD1 protein is caused by insufficient
Cu-charging: addition of Cu2+ ions to an extract led to a
7-fold increase in SOD activity (Fig. 4A). Only single bands
at the expected position of SOD1 monomers were seen in
western immunoblots of extracts of the spinal cords from terminally ill mice (Fig. 4B).
As analyzed by a filter trap assay for aggregates, the spinal
cords from terminal homozygous wt-hSOD1 mice contained
large amounts of hSOD1 aggregates (Fig. 4C). The brain also
contained significant amounts of aggregates, at around 40%
of the level seen in the spinal cord (comparison in four mice).
Despite similar expression of the hSOD1 protein (Table 3),
no aggregates were detected in the liver nor in the skeletal
muscle (Fig. 4C). No significant amounts of aggregates were
found at 100 days in homozygous and hemizygous mice and
350 days in hemizygous wt-hSOD1 mice. At 600 days, aggregates were found in the spinal cords and brain also from hemizygous mice, at around a 1/10th of the levels seen in terminal
Downloaded from http://hmg.oxfordjournals.org/ by guest on April 30, 2016
SOD1 was seen in brainstem motor neurons as well as in
neurons in the motor areas of the cortex as defined in
Tennant et al. (22). There was also vacuolization in the
ventral horn neuropil, which became more pronounced as
the disease progressed. The vacuoles were lined with material
immunopositive for misfolded SOD1, and in terminal mice,
this was the dominant pathology. Vacuoles were also seen in
the ventral funiculus and ventral roots, indicating that at
least some of the neuropil vacuoles represent axonal
damage. Astrogliosis was seen in the 100-day-old wt-hSOD1
homozygotes and was aggravated in the terminal mice.
Some of the glial cells also showed intranuclear staining for
misfolded SOD1 (Fig. 3B and G, arrowhead). Interestingly,
age-matched wt-hSOD1 hemizygotes also had inclusions of
misfolded SOD1 in the cytoplasm and also vacuolization in
the neuropil, resembling the picture in 100-day-old
wt-hSOD1 homozygotes (Fig. 3I).
To quantify the damage, ventral horn neurons were counted
by stereology (Table 2). The thoracic part of the degenerating
spinal cord was chosen for this study, since it can be precisely
delimited generating high precision in the counting and calculations. Terminally ill homozygous wt-hSOD1 mice had lost
41% of the neurons. Remaining thoracic ventral horn
neurons in end-stage G93A and D90A mice have previously
been counted using the same protocol, yielding similar
results (45 and 40% losses, respectively) (19). The loss in agematched hemizygotes (33%) was somewhat less than that previously found at a later stage (570 days) in hemizygous
wt-hSOD1 mice on C57Bl/6 background (38%) (19).
The terminal wt-hSOD1 homozygous mice and the agematched wt-hSOD1 hemizygotes all had cytoplasmic
hSOD1-positive inclusions in the axons and neurons of the
hippocampus. Vacuolization in the hippocampal area was
found already at 100 days in wt-hSOD1 homozygotes and in
the terminal homozygotes almost all neurons in the subiculum
showed heavy vacuolization (Fig. 3J). For comparison, four
terminally ill mice of our other ALS models were examined
by SOD1 immunohistochemistry, as were around 600-dayold hemizygous wt-hSOD1 mice on C57Bl/6 background.
Misfolded hSOD1 was seen in at least some hippocampal
axons and neurons in all transgenic mice, most staining seen
in the cornu ammonis 1 and 2 areas. As in the homozygous
wt-hSOD1 mice, heavy vacuolization in the subiculum was
seen in D90A and the hemizygous wt-hSOD1 mice, whereas
this area was unremarkable in G93A, G85R and G127X mice.
In the cerebellum, Purkinje cells showed mostly cytoplasmic staining for misfolded hSOD1. This was seen already in
100-day-old wt-hSOD1 homozygotes and also in
350-day-old wt-hSOD1 hemizygotes. In terminally ill homozygotes, there was a loss of Purkinje cells, which was estimated to be around 25%. The remaining Purkinje cells were
heavily surrounded by vacuoles and showed severe damage
and disruption of integrity (Fig. 3I). In the surrounding neuropil as well as in the granular layer of the cerebellum, many
hSOD1-positive vacuoles and aggregates were seen (Fig. 3H
and I). In our other ALS model mice, the strongest staining
for misfolded hSOD1 was likewise seen in Purkinje cells,
which, however, did not show any cell loss, except in one
G85R mouse in which a 5% loss was estimated. In the
600-day-old hemizygous wt-hSOD1 transgenes, however,
there was vacuolization in the Purkinje cell layer as well as
a cell loss estimated at 5 – 10%.
Human Molecular Genetics, 2013, Vol. 22, No. 1
55
Table 3. Analysis of hSOD1 content, percentage of C57–C146 disulfide bond reduction and SOD1 activity
SOD1 % reduced
SOD1 activity (kU/g ww)
350 days/terminal
SOD1 (mg/g ww)
SOD1 % reduced
SOD1 activity (kU/g ww)
3.34 + 0.94
1.35 + 0.38
11.4 + 0.4
6.0 + 0.4
120.0 + 5.4
115.0 + 7.1
12.2 + 0.6
4.14 + 0.40
1.55 + 0.69
3.9 + 0.2
6.8 + 0.4
141.0 + 7.3
119.0 + 9.2
11.4 + 0.8
3.44 + 0.81
1.60 + 0.04
8.4 + 0.7
8.5 + 0.7
135.0 + 9.7
125.0 + 2.3
16.9 + 0.6
4.67 + 0.87
1.71 + 0.32
6.4 + 0.2
7.0 + 0.3
142.0 + 1.7
157.0 + 0.7
16.9 + 0.7
3.06 + 0.71
1.64 + 0.44
8.5 + 0.7
6.1 + 0.6
143.0 + 8.5
139.0 + 9.1
15.8 + 0.6
4.54 + 0.79
1.97 + 0.42
3.9 + 0.4
7.3 + 0.3
169.0 + 36.2
158.0 + 10.9
14.5 + 1.5
3.37
1.52
527
371
100
4.19
2.48
574
265
45
1.21
0.80
117
50
7.6
1.55
0.73
196
102
9.9
The spinal cord, brain and cerebellum were analyzed from three mice of all genotypes of both ages. Data presented are mean + SD. At 100 days, the contents of the
total soluble protein in the spinal cord, brain, cerebellum, liver and skeletal muscle were 83, 119, 105, 249 and 123 mg/g wet weight (ww), respectively.
homozygous mice. For comparison, terminal G93A mice were
examined (Fig. 4C). In these, the highest levels of aggregates
were also found in the spinal cord, but the levels in the brain
were relatively lower: around 4% of those in the spinal cord.
The mean value in the filter trap assay of the spinal cords
from end-stage homozygous wt-hSOD1 mice was 65% (n ¼
4) of that in G93A mice (n ¼ 5). In comparison, the results
for D90A, G85R and G127X mice were 88% (n ¼ 5), 119%
(n ¼ 3) and 36% (n ¼ 4), respectively, of those found in
G93A mice. The brain/spinal cord ratios were also low in the
other mutant hSOD1-expressing mice: around 2, 4 and 10%
in the D90A (n ¼ 3), G85R (n ¼ 3) and G127X (n ¼ 4)
models, respectively.
DISCUSSION
Our principal finding is that mice that express wt-hSOD1 at a
rate close to that of the mutant enzyme in G93A transgenics
develop a fatal ALS-like disease. In terminally ill mice, the
loss of ventral horn neurons is similar in the two models
(Table 2) (19). The vacuolization, gliosis and other pathological changes in the spinal cords (Fig. 3A, B, F and G) are also
similar to those previously seen in G93A and D90A transgenic
mice (14,19). There is also considerable aggregation of
hSOD1 in the spinal cords, as in mice carrying mutant
hSOD1s (Fig. 4C).
There are, however, also features different from those in
mice expressing mutant hSOD1s. The mice develop an
ataxic staggering gait, earlier in homozygous than in heterozygous wt-hSOD1 transgenics, which is seen both on CBA and
C57Bl/6 background. The relative amounts of hSOD1 aggregates in the brain were higher than found in mice expressing
G93A (Fig. 4C) and other mutant hSOD1s.
Although the motor system impairment is most prominent
in ALS, other parts of the CNS can also become involved.
This was first observed already in the 19th century (24).
More recently, imaging (25,26) and histopathological studies
(27– 30) have established the occurrence of multisystem pathology in the CNS including the cerebellum in ALS patients
with and without SOD1 mutations. Lending further support
for the involvement of the cerebellum is the observation of
overt cerebellar ataxia in some cases of ALS with SOD1 mutations (31). For these reasons, we examined the brain and cerebellum in the homozygous wt-hSOD1 transgenic mice and for
comparison in our other hSOD1 transgenic models. The pathological findings were found to vary considerably between the
ALS model mice. The distinct vacuolization of the subiculum
of the homozygous wt-hSOD1 mice appeared also in terminal
D90A mice and the 600-day-old hemizygous wt-hSOD1 transgenes but not in G93A, G85R and G127X mice. It has also
previously been observed in hemizygous wt-hSOD1 transgenes (13,32). The single unique pathological change associated with wt-hSOD1 overexpression in the areas here
examined was the disturbance and loss of Purkinje cells.
Perhaps, the staggering gait of the mice is related to this
pathology.
The amounts of hSOD1 in the CNS were high in homozygous wt-hSOD1 transgenic mice, four times those in G93A
transgenic mice (14). The difference versus the latter is apparently explained by the lower stability of the G93A mutant
(33– 35), leading to greater population of un/misfolded molecular species which become targeted for degradation (19).
The levels of the hSOD1 protein in the CNS vary widely
between mutants, e.g. the ratios between D90A and G217X
hSOD1 proteins are around 100 in humans and 40 in transgenic mice (6,14). This suggests that ALS is not caused by the
bulk of essentially natively folded hSOD1 species, but rather
by minute amounts of misfolded and probably disulfidereduced hSOD1 species (6,36). Loss of the disulfide bond
leads to a greater propensity of hSOD1 to aggregate in vitro
Downloaded from http://hmg.oxfordjournals.org/ by guest on April 30, 2016
Spinal cord
Homozygous
Hemizygous
CBA control
Brain
Homozygous
Hemizygous
CBA control
Cerebellum
Homozygous
Hemizygous
CBA control
Liver
Homozygous
Hemizygous
CBA control
Muscle
Homozygous
Hemizygous
CBA control
100 days
SOD1 (mg/g ww)
56
Human Molecular Genetics, 2013, Vol. 22, No. 1
(37,38), and the hSOD1 present in spinal cord aggregates lacks
the C57 – C146 disulfide bond (39,40). The aggregates
detected here should therefore be derived from misfolded subfractions of the large amounts of C57 – C146 bond reduced
hSOD1 present in the CNS of the homozygous wt-hSOD1
transgenic mice (Table 3). The proportion of disulfide-reduced
wt-hSOD1 in the spinal cord was reduced in the terminal stage
(Table 3). Perhaps, this can be explained by the terminal oxidative stress seen in the transgenic models (41). Whether
SOD1 aggregates are the offenders in ALS pathogenesis or
whether they should be seen as terminal markers for the presence of more toxic oligomeric or monomeric misfolded SOD1
species is currently unknown.
A word of caution is necessary because of the great overexpression of the hSOD1 protein in the current homozygous
wt-hSOD1 mice. Such overexpression, although not as extensive, is also seen in mice expressing wild-type-like hSOD1
mutants, and it might produce artifacts unrelated to the core
ALS-causing mechanisms. There is incomplete Cu-charging
of the hSOD1 variants despite 3 – 5-fold increases in copper
chaperone for SOD (CCS) (14). This CCS induction is probably insufficient to charge the hSOD1s which are overexpressed to much larger extents. It also suggests that there is
a reduced availability of Cu ions in the tissue (42) which
might cause adverse effects. Treatment of G93A mice with a
cell-permeant Cu chelator has, however, been found to
prolong the lifespan, arguing against a toxic effect of Cu deficiency in models expressing wild-type-like hSOD1s (43).
Another effect is marked overloading of the mitochondrial
intermembrane space (IMS) with hSOD1 (44), which is associated with vacuolization and other morphological changes
(Fig. 3) (13,14,19,32). It is not with certainty known to
which extent this artifact contributes to the disease phenotype
of the mice. In this regard, a series of studies in mice overexpressing CCS suggest that IMS overloading at least with
mutant hSOD1s can cause severe adverse effects (45– 47).
Downloaded from http://hmg.oxfordjournals.org/ by guest on April 30, 2016
Figure 4. Examinations of the wt-hSOD1 protein in the transgenic mice. (A) Effect of addition of CuSO4 to an extract of the spinal cord from a homozygous
wt-hSOD1 transgenic mouse. CuSO4 at the concentrations indicated was added to aliquots of a 1 + 25 extract of the spinal cord from a 100-day-old wt-hSOD1
homozygous transgenic mouse (filled circles). The extracts were incubated overnight at 48C and were then analyzed for SOD activity using the KO2 assay (50).
The SOD activity of a similarly treated extract from a CBA control mouse rose from 520 to 675 U/ml (a 30% increase), suggesting the presence of small amounts
of murine SOD1 not charged with Cu (open circles). Extraction buffer with CuSO4 added did not show any SOD activity. (B) Western immunoblots of the spinal
cord extracts from homozygous and hemizygous wt-hSOD1 transgenic mice. The blots were developed with the 24–39 anti-hSOD1 antibody which does not
react with murine SOD1. Only a band at the expected position of hSOD1 was found; no aberrant bands could be found even after long exposure as in the figure.
The positions of the molecular weight markers (kDa) are marked on the left-hand side. (C) Aggregates of hSOD1 in different tissues analyzed with a filter trap
assay. The brain, spinal cord, cerebellum, liver and skeletal muscle from a terminal wt-hSOD1 and a terminal G93A hSOD1 transgenic mouse were examined.
Several mice were analyzed and the results presented are typical for the two genotypes. The dot-blot lanes have been moved from their original positions in the
filters.
Human Molecular Genetics, 2013, Vol. 22, No. 1
in so far examined ALS patients carrying SOD1 mutations.
Hypothetically, toxicity caused by misfolded hSOD1s might
be a final common pathway in ALS pathogenesis.
In conclusion, we here show that wt-hSOD1 has the ability
to cause ALS, although it is lower than that of mutant
hSOD1s. The variation in phenotypes and penetrance in families expressing mutant hSOD1s and the existence of recessive
and dominant inheritance associated with the D90A mutation
suggest that genetic, environmental and lifestyle-related
factors influence the susceptibility to hSOD1-induced ALS
(1). Possibly such factors occasionally induce the wild-type
hSOD1 to cause the disease.
MATERIALS AND METHODS
Mice
The G1H G93A mice used (12) were backcrossed .30 generations in C57Bl/6 mice. Mice hemizygous for the insertion site
of a wt-hSOD1 transgene (N1029) (12) in C57Bl/6 background
were backcrossed 8 – 10 generations into CBA background.
These mice were in turn crossed for the production of mouse
homozygous for the wt-hSOD1 insertion. For comparison,
mice expressing D90A (19), G127X (6) and G85R (49)
mutant hSOD1s were also examined. All were backcrossed
10– 30 generations into C57Bl/6 background. The mice were
checked for symptoms at least every third day and they were
weighed once a week. The initial ALS-like symptoms considered were deficient splaying of the hindlegs when held by the
tail. The mice were deemed terminally ill if they could not
right themselves within 5 s after being put on their side. The
use and maintenance of the mice and the experimental protocols described in this article were approved by the Ethics Committee for Animal Research at Umeå University.
Antibodies
Antibodies to peptides corresponding to amino acids 24– 39,
57– 72 and 131– 153 in hSOD1 were coupled to keyhole
limpet hemocyanin and raised in rabbits as described previously (6,7). The antibodies were purified from sera using Protein
A-Sepharose (GE Healthcare, Uppsala, Sweden) followed by
Sulfolink gel with the respective peptides coupled (Pierce,
Rockford, IL, USA). These antibodies only react with misfolded hSOD1 species and show no reactivity with the
native protein (7,8).
Histopathology
Wild-type hemi- and homozygotic transgenic mice and nontransgenic control mice were anesthetized by an intraperitoneal injection of midazolam, fentanyl and fluanisone and
killed by perfusion fixation through the heart with 4% paraformaldehyde in phosphate buffer (pH 7.6). Animals were
studied at ≏100 and 350 days of age (if applicable) and at terminal disease as defined previously. Five to eight mice of each
age and genotype were examined. After fixation, the central
nervous system was dissected in situ and the cervicothoracic
and thoracolumbar borders as well as the junction between
the brainstem and the spinal cord were identified by guidance
Downloaded from http://hmg.oxfordjournals.org/ by guest on April 30, 2016
The overexpression of CCS drastically shortened the lifespan
of mice expressing the wild-type-like hSOD1 mutants G93A
and G37R, concomitantly with markedly increased proportions of disulfide-reduced hSOD1 in the tissue as well as
marked increases in mitochondrial IMS hSOD1 loading and
vacuolization. Unlike in single hSOD1 transgenics, the terminal disease in the double-transgenic mice was not associated
with hSOD1 aggregation. CCS overexpression also caused
moderately increased loading of wild-type hSOD1 in mitochondria in N1029 hemizygous wt-hSOD1 mice, but in this
case no adverse effects could be detected. Notably, in these
mice, the proportion of disulfide-reduced hSOD1 was
decreased by the CCS overexpression. Another phenomenon
that seems to be related to the mitochondrial hSOD1 overloading and morphological changes is axonal transport deficits
which are seen in both G93A and G37R mice (48). Such deficits are, however, also found in N1029 hemizygous
wt-hSOD1 mice but not in G85R mice. This suggests that
the transport deficits are tolerated and that hSOD1-induced
ALS is caused by other mechanisms. To conclude, the wildtype and wild-type-like hSOD1 mutants might cause disease
phenotypes which stem from a combination of ALS-relevant
effects and artifacts caused by the large overexpression of
the hSOD1 protein. From the current knowledge, there are
no indications that the great overexpression of wild-type
hSOD1 would cause more irrelevant effects than the
wild-type-like mutants.
Related to expression rates (¼mRNA), the D90A mutant
hSOD1 has the lowest potential to cause ALS of the mutants
expressed in the transgenic models kept in our laboratory
(14,19). Homozygous D90A mice and hemizygous
wt-hSOD1 mice have similar hSOD1 mRNA levels (14).
Based on the loss of spinal ventral neurons and other evidence
of pathology, wt-hSOD1 has been estimated to have a neurotoxicity between half of and equal to that of the D90A mutant
(19). While hemizygous D90A mice have normal lifespans,
the homozygous mice live around 430 days. According to
our previous assessment, homozygous wt-hSOD1 mice
should have a somewhat shorter lifespan than that, which is
what we found here.
N1019 hemizygous wt-hSOD1 mice have commonly been
used as controls for hSOD1 overexpression in studies of
G93A and other hSOD1 transgenic ALS models. This is unfortunate for two reasons. (I) The relatively low hSOD1 expression rate, which was reported in the original paper (12),
makes it a less than perfect control for the overexpression of
presumed innocuous hSOD1. (II) It is here shown that it can
exert ALS-provoking effects. Thus, alterations seen in the
control and therefore disregarded may have been relevant.
An antibody reactive with misfolded wt-hSOD1 was recently
found to label motor axons in a carrier of an FUS mutation as
well as in sporadic ALS patients displaying cytosolic
TDP43-immunoreactive inclusions (10). Moreover, cytosolic
expression of human mutant TDP43 or FUS and wild-type
TDP43 in cultured human neuroblastoma cells was found to
induce misfolding of the endogenous wt-hSOD1 (10). Thus, misfolding of wt-hSOD1 might occur secondarily to TDP43 or FUS
pathology. Since mutant hSOD1s owing to reduced structural
stabilities are prone to misfold spontaneously, the findings
might explain the absence of TDP43-immunoreactive inclusions
57
58
Human Molecular Genetics, 2013, Vol. 22, No. 1
Stereology
From the upper end of each of the six paraffin blocks containing the thoracic spinal cord from terminally ill homozygous
wt-hSOD1 mice and from around 350-day-old hemizygous
and control CBA mice, 50 mm thick sections were cut on a
sliding microtome, mounted on glass slides and stained with
cresyl violet. Cells with identifiable nucleolus in the nuclei
were counted and the total numbers of neurons in the thoracic
spinal cords were calculated as previously described (19).
Tissue homogenization
Mice were killed by intraperitoneal injection of pentobarbital.
The dissected tissues were homogenized with an Ultraturrax
apparatus (IKA, Staufen, Germany) for 1 min and sonicated
for 1 min at 48C in 25 volumes of ice-cold pH 7.0 buffer
solution composed of 137 mM NaCl, 2.7 mM KCl, 4.3 mM
Na2HPO4, 1.4 mM KH2PO4, 1.8 mM ethylenediaminetetraacetic acid, 1 mM dithithreitol, and the antiproteolytic cocktail
Completew (Roche Diagnostics, Basel, Switzerland).
Immunoblots and quantifications
Common western immunoblots were generally carried out as
previously described (14) using the 24– 39 antipeptide antibody which is specific for hSOD1. The chemiluminescence
of the blots was recorded in a ChemiDoc apparatus and analyzed with Quantity One software (Bio-Rad Laboratories).
For quantification of hSOD1s in immunoblots, wt-hSOD1
with the concentration determined by quantitative amino
acid analysis was used as the original standard (18).
For analysis of proportion of reduced C46-C157 disulfide
bond, 40 mM of iodoacetamide was added to the homogenization buffer to alkylate-free thiol groups. Western immunoblots
were carried out with sample buffer containing 40 mM
iodoacetamide but no reductant. The proportion of reduced
wt-hSOD1 was then determined using as standard stepwise
diluted homogenates run in parallel with reductant in the
sample buffer (14).
Filter trap assay for aggregates
The 1 + 25 tissue homogenates were further diluted 1 + 20 in
homogenization buffer containing 1% NP40, sonicated for
30 s and then centrifuged at 200g for 10 min. The supernatants
were then diluted stepwise 1 + 1 in homogenization buffer
and 100 ml captured on a 0.22 mm cellulose acetate filter in a
96-well dot-blot apparatus (Whatman GmbH, Dassel,
Germany). Following 3 × 300 ml washes with homogenization
buffer, the filters were blocked and developed with the 57– 72
anti-hSOD1 peptide antibody and subsequently quantified in
the Chemidoc apparatus similarly to the western immunoblots.
A homogenate of a spinal cord from a terminal G93A transgenic
mouse, kept frozen in multiple aliquots, was handled in a similar
way and always run in parallel on the filters as a standard.
Analysis of SOD activity
Enzymatic activity of SOD was determined with the direct
spectrophotometric assay using KO2 (50). One unit is
defined as the activity that brings about a decay of superoxide
at a rate of 0.1 s21 in 3 ml buffer. One unit corresponds to
4.3 ng fully Cu- and Zn-charged wt-hSOD1 (18).
Northern blot
RNA from the mouse brains was extracted using the Trizol
reagent (Invitrogen) and was then subjected to northern blotting utilizing an Ambionw NorthernMaxw-Gly Kit (Invitrogen), all according to the manufacturer’s instructions. The
samples were normalized against b-actin, and the quantifications were carried out twice on three 100-day-old mice of
each genotype. Probes were labeled using MegaPrime
random labeling kit (Amersham Biosciences). As template
for the b-actin probe, the DECA-template b-actin mouse supplied with the Ambionw NorthernMaxw-Gly Kit was used. As
template for the SOD1 probe a polymerase chain reaction
(PCR) fragment was used, purified employing High Pure
PCR Product Purification kit (Roche Diagnostics). The
primers used were 5′ - TGCTAGCTGTAGAAATGTATCC
TGA-3′ and 5′ -TTCACAGGCTTGAATGACAAA-3′ , yielding a 306 bp amplicon of the 3′ UTR region that is not homologous to the mouse transcript. Bands were visualized with a
Storage phosphor screen (GE Healthcare) and scanned using
a Typhoon 9400 variable mode imager (GE Healthcare). The
amounts of SOD1 and b-actin mRNA were analyzed with
Quantity One Software (Bio-Rad Laboratories).
ACKNOWLEDGEMENTS
We thank Eva Bern, Karin Hjertkvist, Ulla-Stina Spetz,
Ann-Charloth Nilsson and Agneta Öberg for expert technical
assistance.
Conflict of Interest statement. None declared.
Downloaded from http://hmg.oxfordjournals.org/ by guest on April 30, 2016
by the ventral roots. The cervical, thoracic and lumbosacral
spinal cord was dissected free, and these parts were then
divided equally into six blocks, which were embedded separately in paraffin wax. The uppermost blocks of the cervical,
thoracic and lumbosacral spinal cord, as well as the second
lowermost block of the lumbosacral spinal cord, were used
for the histopathology investigations. Sections from each
piece were stained with hematoxylin and eosin as well as
with antibodies toward GFAP (Dako, Glostrup, Denmark),
ubiquitin (Dako) and with the 57– 72 and 131 – 153 antihSOD1 peptide rabbit antibodies described previously (7,8).
If not otherwise stated, the results presented in the Results
section correspond to findings at all three levels of the spinal
cord. The immunohistochemistry was performed using the
Ventana ES immunohistochemistry system and the standard
protocol, which was preceded by microwave irradiation of
the sections in citric acid buffer for 5 min. The primary antibodies were detected with biotin-conjugated secondary antibodies coupled to an avidin-horseradish peroxidase
conjugate. The complexes formed were visualized using aminoethylcarbazole as the precipitating enzyme product. Sections were counterstained with hematoxylin, washed and
mounted with glycerin gelatin.
Human Molecular Genetics, 2013, Vol. 22, No. 1
FUNDING
This work was supported by the Swedish Science Council, the
Hållsten Foundation/the Brain Fund, the Swedish Association
for Individuals with Neurological Disabilities, the Torsten
Söderberg foundation, the Ulla-Carin Lindquist ALSFoundation and the Research Fund of the Medical Faculty of
Umeå University.
REFERENCES
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
superoxide dismutase-1 in CNS of transgenic amyotrophic lateral sclerosis
models. Brain, 129, 451– 464.
Fukada, K., Nagano, S., Satoh, M., Tohyama, C., Nakanishi, T., Shimizu,
A., Yanagihara, T. and Sakoda, S. (2001) Stabilization of mutant Cu/Zn
superoxide dismutase (SOD1) protein by coexpressed wild SOD1 protein
accelerates the disease progression in familial amyotrophic lateral
sclerosis mice. Eur. J. Neurosci., 14, 2032–2036.
Deng, H.X., Shi, Y., Furukawa, Y., Zhai, H., Fu, R., Liu, E., Gorrie, G.H.,
Khan, M.S., Hung, W.Y., Bigio, E.H. et al. (2006) Conversion to the
amyotrophic lateral sclerosis phenotype is associated with intermolecular
linked insoluble aggregates of SOD1 in mitochondria. Proc. Natl Acad.
Sci. USA, 103, 7142– 7147.
Prudencio, M., Durazo, A., Whitelegge, J.P. and Borchelt, D.R. (2010) An
examination of wild-type SOD1 in modulating the toxicity and
aggregation of ALS-associated mutant SOD1. Hum. Mol. Genet., 19,
4774–4789.
Marklund, S.L., Andersen, P.M., Forsgren, L., Nilsson, P., Ohlsson, P.I.,
Wikander, G. and Oberg, A. (1997) Normal binding and reactivity of
copper in mutant superoxide dismutase isolated from amyotrophic lateral
sclerosis patients. J. Neurochem., 69, 675–681.
Jonsson, P.A., Graffmo, K.S., Brannstrom, T., Nilsson, P., Andersen, P.M.
and Marklund, S.L. (2006) Motor neuron disease in mice expressing the
wild type-like D90A mutant superoxide dismutase-1. J. Neuropathol. Exp.
Neurol., 65, 1126– 1136.
Synofzik, M., Ronchi, D., Keskin, I., Basak, A.N., Wilhelm, C., Gobbi, C.,
Birve, A., Biskup, S., Zecca, C., Fernandez-Santiago, R. et al. (2012)
Mutant superoxide dismutase-1 indistinguishable from wild-type causes
ALS. Hum. Mol. Genet., 21, 3568– 3574.
Grad, L.I., Guest, W.C., Yanai, A., Pokrishevsky, E., O’Neill, M.A.,
Gibbs, E., Semenchenko, V., Yousefi, M., Wishart, D.S., Plotkin, S.S.
et al. (2011) Intermolecular transmission of superoxide dismutase 1
misfolding in living cells. Proc. Natl Acad. Sci. USA, 108, 16398–16403.
Tennant, K.A., Adkins, D.L., Donlan, N.A., Asay, A.L., Thomas, N.,
Kleim, J.A. and Jones, T.A. (2011) The organization of the forelimb
representation of the C57BL/6 mouse motor cortex as defined by
intracortical microstimulation and cytoarchitecture. Cereb. Cortex, 21,
865– 876.
Andersen, P.M., Nilsson, P., Forsgren, L. and Marklund, S.L. (1998)
CuZn-superoxide dismutase, extracellular superoxide dismutase, and
glutathione peroxidase in blood from individuals homozygous for
Asp90Ala CuZu-superoxide dismutase mutation. J. Neurochem., 70, 715–
720.
Dornbluth, O. (1889) Anatomische untersuchung eines falles von
amyotrophischer lateralsklerose. Neurologisches Zentralblatt, 13, 24–33.
Turner, M.R., Hammers, A., Al-Chalabi, A., Shaw, C.E., Andersen, P.M.,
Brooks, D.J. and Leigh, P.N. (2005) Distinct cerebral lesions in sporadic
and ‘D90A’ SOD1 ALS: studies with [11C]flumazenil PET. Brain, 128,
1323–1329.
Turner, M.R., Rabiner, E.A., Al-Chalabi, A., Shaw, C.E., Brooks, D.J.,
Leigh, P.N. and Andersen, P.M. (2007) Cortical 5-HT1A receptor binding
in patients with homozygous D90A SOD1 vs sporadic ALS. Neurology,
68, 1233–1235.
Mizutani, T., Sakamaki, S., Tsuchiya, N., Kamei, S., Kohzu, H., Horiuchi,
R., Ida, M., Shiozawa, R. and Takasu, T. (1992) Amyotrophic lateral
sclerosis with ophthalmoplegia and multisystem degeneration in patients
on long-term use of respirators. Acta Neuropathol., 84, 372–377.
Takehisa, Y., Ujike, H., Ishizu, H., Terada, S., Haraguchi, T., Tanaka, Y.,
Nishinaka, T., Nobukuni, K., Ihara, Y., Namba, R. et al. (2001) Familial
amyotrophic lateral sclerosis with a novel Leu126Ser mutation in the
copper/zinc superoxide dismutase gene showing mild clinical features and
Lewy body-like hyaline inclusions. Arch. Neurol., 58, 736 –740.
Geser, F., Brandmeir, N.J., Kwong, L.K., Martinez-Lage, M., Elman, L.,
McCluskey, L., Xie, S.X., Lee, V.M. and Trojanowski, J.Q. (2008)
Evidence of multisystem disorder in whole-brain map of pathological
TDP-43 in amyotrophic lateral sclerosis. Arch. Neurol., 65, 636– 641.
Tateishi, T., Hokonohara, T., Yamasaki, R., Miura, S., Kikuchi, H., Iwaki,
A., Tashiro, H., Furuya, H., Nagara, Y., Ohyagi, Y. et al. (2010) Multiple
system degeneration with basophilic inclusions in Japanese ALS patients
with FUS mutation. Acta Neuropathol., 119, 355– 364.
Andersen, P.M., Forsgren, L., Binzer, M., Nilsson, P., Ala-Hurula, V.,
Keranen, M.L., Bergmark, L., Saarinen, A., Haltia, T., Tarvainen, I. et al.
(1996) Autosomal recessive adult-onset amyotrophic lateral sclerosis
associated with homozygosity for Asp90Ala CuZn-superoxide dismutase
Downloaded from http://hmg.oxfordjournals.org/ by guest on April 30, 2016
1. Andersen, P.M. and Al-Chalabi, A. (2011) Clinical genetics of
amyotrophic lateral sclerosis: what do we really know? Nat. Rev. Neurol.,
7, 603– 615.
2. Forman, M.S., Trojanowski, J.Q. and Lee, V.M. (2004)
Neurodegenerative diseases: a decade of discoveries paves the way for
therapeutic breakthroughs. Nat. Med., 10, 1055–1063.
3. Mackenzie, I.R., Bigio, E.H., Ince, P.G., Geser, F., Neumann, M., Cairns,
N.J., Kwong, L.K., Forman, M.S., Ravits, J., Stewart, H. et al. (2007)
Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis
from amyotrophic lateral sclerosis with SOD1 mutations. Ann. Neurol.,
61, 427–434.
4. Kato, S., Takikawa, M., Nakashima, K., Hirano, A., Cleveland, D.W.,
Kusaka, H., Shibata, N., Kato, M., Nakano, I. and Ohama, E. (2000) New
consensus research on neuropathological aspects of familial amyotrophic
lateral sclerosis with superoxide dismutase 1 (SOD1) gene mutations:
inclusions containing SOD1 in neurons and astrocytes. Amyotroph.
Lateral Scler. Other Motor Neuron Disord., 1, 163– 184.
5. Bruijn, L.I., Houseweart, M.K., Kato, S., Anderson, K.L., Anderson, S.D.,
Ohama, E., Reaume, A.G., Scott, R.W. and Cleveland, D.W. (1998)
Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant
independent from wild-type SOD1. Science, 281, 1851– 1854.
6. Jonsson, P.A., Ernhill, K., Andersen, P.M., Bergemalm, D., Brannstrom,
T., Gredal, O., Nilsson, P. and Marklund, S.L. (2004) Minute quantities of
misfolded mutant superoxide dismutase-1 cause amyotrophic lateral
sclerosis. Brain, 127, 73–88.
7. Forsberg, K., Jonsson, P.A., Andersen, P.M., Bergemalm, D., Graffmo,
K.S., Hultdin, M., Jacobsson, J., Rosquist, R., Marklund, S.L. and
Brannstrom, T. (2010) Novel antibodies reveal inclusions containing
non-native SOD1 in sporadic ALS patients. PLoS One, 5, e11552.
8. Forsberg, K., Andersen, P.M., Marklund, S.L. and Brannstrom, T. (2011)
Glial nuclear aggregates of superoxide dismutase-1 are regularly present
in patients with amyotrophic lateral sclerosis. Acta Neuropathol., 121,
623–634.
9. Bosco, D.A., Morfini, G., Karabacak, N.M., Song, Y., Gros-Louis, F.,
Pasinelli, P., Goolsby, H., Fontaine, B.A., Lemay, N., McKenna-Yasek,
D. et al. (2010) Wild-type and mutant SOD1 share an aberrant
conformation and a common pathogenic pathway in ALS. Nat. Neurosci.,
13, 1396–1403.
10. Pokrishevsky, E., Grad, L.I., Yousefi, M., Wang, J., Mackenzie, I.R. and
Cashman, N.R. (2012) Aberrant localization of FUS and TDP43 is
associated with misfolding of SOD1 in amyotrophic lateral sclerosis.
PLoS One, 7, e35050.
11. Haidet-Phillips, A.M., Hester, M.E., Miranda, C.J., Meyer, K., Braun, L.,
Frakes, A., Song, S., Likhite, S., Murtha, M.J., Foust, K.D. et al. (2011)
Astrocytes from familial and sporadic ALS patients are toxic to motor
neurons. Nat. Biotechnol., 29, 824–828.
12. Gurney, M.E., Pu, H., Chiu, A.Y., Dal Canto, M.C., Polchow, C.Y.,
Alexander, D.D., Caliendo, J., Hentati, A., Kwon, Y.W., Deng, H.X. et al.
(1994) Motor neuron degeneration in mice that express a human Cu,Zn
superoxide dismutase mutation. Science, 264, 1772– 1775.
13. Jaarsma, D., Haasdijk, E.D., Grashorn, J.A., Hawkins, R., van Duijn, W.,
Verspaget, H.W., London, J. and Holstege, J.C. (2000) Human Cu/Zn
superoxide dismutase (SOD1) overexpression in mice causes
mitochondrial vacuolization, axonal degeneration, and premature
motoneuron death and accelerates motoneuron disease in mice expressing
a familial amyotrophic lateral sclerosis mutant SOD1. Neurobiol. Dis., 7,
623–643.
14. Jonsson, P.A., Graffmo, K.S., Andersen, P.M., Brannstrom, T., Lindberg,
M., Oliveberg, M. and Marklund, S.L. (2006) Disulphide-reduced
15.
59
60
32.
33.
34.
35.
36.
38.
39.
40.
mutation. A clinical and genealogical study of 36 patients. Brain, 119,
1153– 1172.
Dal Canto, M.C. and Gurney, M.E. (1995) Neuropathological changes in
two lines of mice carrying a transgene for mutant human Cu,Zn SOD, and
in mice overexpressing wild type human SOD: a model of familial
amyotrophic lateral sclerosis (FALS). Brain Res., 676, 25– 40.
Rodriguez, J.A., Valentine, J.S., Eggers, D.K., Roe, J.A., Tiwari, A.,
Brown, R.H. Jr and Hayward, L.J. (2002) Familial amyotrophic lateral
sclerosis-associated mutations decrease the thermal stability of distinctly
metallated species of human copper/zinc superoxide dismutase. J. Biol.
Chem., 277, 15932–15937.
Lindberg, M.J., Tibell, L. and Oliveberg, M. (2002) Common
denominator of Cu/Zn superoxide dismutase mutants associated with
amyotrophic lateral sclerosis: decreased stability of the apo state. Proc.
Natl Acad. Sci. USA, 99, 16607– 16612.
Lindberg, M.J., Bystrom, R., Boknas, N., Andersen, P.M. and Oliveberg,
M. (2005) Systematically perturbed folding patterns of amyotrophic
lateral sclerosis (ALS)-associated SOD1 mutants. Proc. Natl Acad. Sci.
USA, 102, 9754–9759.
Zetterstrom, P., Stewart, H.G., Bergemalm, D., Jonsson, P.A., Graffmo,
K.S., Andersen, P.M., Brannstrom, T., Oliveberg, M. and Marklund, S.L.
(2007) Soluble misfolded subfractions of mutant superoxide dismutase-1s
are enriched in spinal cords throughout life in murine ALS models. Proc.
Natl Acad. Sci. USA, 104, 14157–14162.
Furukawa, Y., Kaneko, K., Yamanaka, K., O’Halloran, T.V. and Nukina,
N. (2008) Complete loss of post-translational modifications triggers
fibrillar aggregation of SOD1 in the familial form of amyotrophic lateral
sclerosis. J. Biol. Chem., 283, 24167– 24176.
Chattopadhyay, M., Durazo, A., Sohn, S.H., Strong, C.D., Gralla, E.B.,
Whitelegge, J.P. and Valentine, J.S. (2008) Initiation and elongation in
fibrillation of ALS-linked superoxide dismutase. Proc. Natl Acad. Sci.
USA, 105, 18663– 18668.
Karch, C.M., Prudencio, M., Winkler, D.D., Hart, P.J. and Borchelt, D.R.
(2009) Role of mutant SOD1 disulfide oxidation and aggregation in the
pathogenesis of familial ALS. Proc. Natl Acad. Sci. USA, 106, 7774–
7779.
Bergemalm, D., Forsberg, K., Srivastava, V., Graffmo, K.S., Andersen,
P.M., Brannstrom, T., Wingsle, G. and Marklund, S.L. (2010) Superoxide
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
dismutase-1 and other proteins in inclusions from transgenic amyotrophic
lateral sclerosis model mice. J. Neurochem., 114, 408– 418.
Ferraiuolo, L., Kirby, J., Grierson, A.J., Sendtner, M. and Shaw, P.J.
(2011) Molecular pathways of motor neuron injury in amyotrophic lateral
sclerosis. Nat. Rev. Neurol., 7, 616–630.
Bertinato, J., Iskandar, M. and L’Abbe, M.R. (2003) Copper deficiency
induces the upregulation of the copper chaperone for Cu/Zn superoxide
dismutase in weanling male rats. J. Nutr., 133, 28–31.
Tokuda, E., Okawa, E. and Ono, S. (2009) Dysregulation of intracellular
copper trafficking pathway in a mouse model of mutant copper/zinc
superoxide dismutase-linked familial amyotrophic lateral sclerosis.
J. Neurochem., 111, 181–191.
Bergemalm, D., Jonsson, P.A., Graffmo, K.S., Andersen, P.M.,
Brannstrom, T., Rehnmark, A. and Marklund, S.L. (2006) Overloading of
stable and exclusion of unstable human superoxide dismutase-1 variants in
mitochondria of murine amyotrophic lateral sclerosis models.
J. Neurosci., 26, 4147–4154.
Son, M., Puttaparthi, K., Kawamata, H., Rajendran, B., Boyer, P.J.,
Manfredi, G. and Elliott, J.L. (2007) Overexpression of CCS in
G93A-SOD1 mice leads to accelerated neurological deficits with severe
mitochondrial pathology. Proc. Natl Acad. Sci. USA, 104, 6072– 6077.
Proescher, J.B., Son, M., Elliott, J.L. and Culotta, V.C. (2008) Biological
effects of CCS in the absence of SOD1 enzyme activation: implications
for disease in a mouse model for ALS. Hum. Mol. Genet., 17, 1728–1737.
Son, M., Fu, Q., Puttaparthi, K., Matthews, C.M. and Elliott, J.L. (2009)
Redox susceptibility of SOD1 mutants is associated with the differential
response to CCS over-expression in vivo. Neurobiol. Dis., 34, 155– 162.
Marinkovic, P., Reuter, M.S., Brill, M.S., Godinho, L., Kerschensteiner,
M. and Misgeld, T. (2012) Axonal transport deficits and degeneration can
evolve independently in mouse models of amyotrophic lateral sclerosis.
Proc. Natl Acad. Sci. USA, 109, 4296– 4301.
Bruijn, L.I., Becher, M.W., Lee, M.K., Anderson, K.L., Jenkins, N.A.,
Copeland, N.G., Sisodia, S.S., Rothstein, J.D., Borchelt, D.R., Price, D.L.
et al. (1997) ALS-linked SOD1 mutant G85R mediates damage to
astrocytes and promotes rapidly progressive disease with
SOD1-containing inclusions. Neuron, 18, 327–338.
Marklund, S. (1976) Spectrophotometric study of spontaneous
disproportionation of superoxide anion radical and sensitive direct assay
for superoxide dismutase. J. Biol. Chem., 251, 7504–7507.
Downloaded from http://hmg.oxfordjournals.org/ by guest on April 30, 2016
37.
Human Molecular Genetics, 2013, Vol. 22, No. 1